337 related articles for article (PubMed ID: 30690293)
1. The impact of chemotherapy on survival of patients with extremity and trunk wall soft tissue sarcoma: revisiting the results of the EORTC-STBSG 62931 randomised trial.
Pasquali S; Pizzamiglio S; Touati N; Litiere S; Marreaud S; Kasper B; Gelderblom H; Stacchiotti S; Judson I; Dei Tos AP; Verderio P; Casali PG; Woll PJ; Gronchi A;
Eur J Cancer; 2019 Mar; 109():51-60. PubMed ID: 30690293
[TBL] [Abstract][Full Text] [Related]
2. High-risk soft tissue sarcomas treated with perioperative chemotherapy: Improving prognostic classification in a randomised clinical trial.
Pasquali S; Colombo C; Pizzamiglio S; Verderio P; Callegaro D; Stacchiotti S; Martin Broto J; Lopez-Pousa A; Ferrari S; Poveda A; De Paoli A; Quagliuolo V; Jurado JC; Comandone A; Grignani G; De Sanctis R; Palassini E; Llomboart-Bosch A; Dei Tos AP; Casali PG; Picci P; Gronchi A
Eur J Cancer; 2018 Apr; 93():28-36. PubMed ID: 29475197
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: A Sarculator-based risk stratification analysis of the ISG-STS 1001 randomized trial.
Pasquali S; Palmerini E; Quagliuolo V; Martin-Broto J; Lopez-Pousa A; Grignani G; Brunello A; Blay JY; Tendero O; Diaz-Beveridge R; Ferraresi V; Lugowska I; Infante G; Braglia L; Merlo DF; Fontana V; Marchesi E; Donati DM; Palassini E; Bianchi G; Marrari A; Morosi C; Stacchiotti S; Bagué S; Coindre JM; Dei Tos AP; Picci P; Bruzzi P; Miceli R; Casali PG; Gronchi A
Cancer; 2022 Jan; 128(1):85-93. PubMed ID: 34643947
[TBL] [Abstract][Full Text] [Related]
4. Assessing the Role of Neoadjuvant Chemotherapy in Primary High-Risk Truncal/Extremity Soft Tissue Sarcomas: An Analysis of the Multi-institutional U.S. Sarcoma Collaborative.
Zaidi MY; Ethun CG; Tran TB; Poultsides G; Grignol VP; Howard JH; Bedi M; Mogal H; Tseng J; Roggin KK; Chouliaras K; Votanopoulos K; Krasnick B; Fields RC; Oskouei S; Reimer N; Monson D; Maithel SK; Cardona K
Ann Surg Oncol; 2019 Oct; 26(11):3542-3549. PubMed ID: 31342400
[TBL] [Abstract][Full Text] [Related]
5. Ten-year follow-up results of perioperative chemotherapy with doxorubicin and ifosfamide for high-grade soft-tissue sarcoma of the extremities: Japan Clinical Oncology Group study JCOG0304.
Tanaka K; Mizusawa J; Naka N; Kawai A; Katagiri H; Hiruma T; Matsumoto Y; Tsuchiya H; Nakayama R; Hatano H; Emori M; Watanuki M; Yoshida Y; Okamoto T; Abe S; Asanuma K; Yokoyama R; Hiraga H; Yonemoto T; Morii T; Ae K; Nagano A; Yoshikawa H; Fukuda H; Ozaki T; Iwamoto Y
BMC Cancer; 2019 Sep; 19(1):890. PubMed ID: 31492159
[TBL] [Abstract][Full Text] [Related]
6. Long-term Outcomes With Ifosfamide-based Hypofractionated Preoperative Chemoradiotherapy for Extremity Soft Tissue Sarcomas.
Pennington JD; Eilber FC; Eilber FR; Singh AS; Reed JP; Chmielowski B; Eckardt JJ; Bukata SV; Bernthal NM; Federman N; Nelson SD; Dry SM; Wang PC; Luu M; Selch MT; Steinberg ML; Kalbasi A; Kamrava M
Am J Clin Oncol; 2018 Dec; 41(12):1154-1161. PubMed ID: 29664796
[TBL] [Abstract][Full Text] [Related]
7. Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study.
Issels RD; Lindner LH; Verweij J; Wust P; Reichardt P; Schem BC; Abdel-Rahman S; Daugaard S; Salat C; Wendtner CM; Vujaskovic Z; Wessalowski R; Jauch KW; Dürr HR; Ploner F; Baur-Melnyk A; Mansmann U; Hiddemann W; Blay JY; Hohenberger P; ;
Lancet Oncol; 2010 Jun; 11(6):561-70. PubMed ID: 20434400
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial.
Woll PJ; Reichardt P; Le Cesne A; Bonvalot S; Azzarelli A; Hoekstra HJ; Leahy M; Van Coevorden F; Verweij J; Hogendoorn PC; Ouali M; Marreaud S; Bramwell VH; Hohenberger P;
Lancet Oncol; 2012 Oct; 13(10):1045-54. PubMed ID: 22954508
[TBL] [Abstract][Full Text] [Related]
9. Trends in the Use of Adjuvant Chemotherapy for High-Grade Truncal and Extremity Soft Tissue Sarcomas.
Squires MH; Ethun CG; Suarez-Kelly LP; Yu PY; Hughes TM; Shelby RD; Tran TB; Poultsides G; Charlson J; Gamblin TC; Tseng J; Roggin KK; Chouliaras K; Votanopoulos K; Krasnick BA; Fields RC; Pollock RE; Grignol V; Cardona K; Howard JH
J Surg Res; 2020 Jan; 245():577-586. PubMed ID: 31494391
[TBL] [Abstract][Full Text] [Related]
10. A randomised, open-label, phase II study of neo/adjuvant doxorubicin and ifosfamide versus gemcitabine and docetaxel in patients with localised, high-risk, soft tissue sarcoma.
Davis EJ; Chugh R; Zhao L; Lucas DR; Biermann JS; Zalupski MM; Feng M; Wong SL; Jacobson J; Zyczynski L; Reinke D; Metko G; Baker LH; Schuetze SM
Eur J Cancer; 2015 Sep; 51(13):1794-802. PubMed ID: 26066736
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant chemoradiotherapy for patients with high-risk extremity and truncal sarcomas: a 10-year single institution retrospective study.
Look Hong NJ; Hornicek FJ; Harmon DC; Choy E; Chen YL; Yoon SS; Nielsen GP; Szymonifka J; Yeap BY; DeLaney TF; Mullen JT
Eur J Cancer; 2013 Mar; 49(4):875-83. PubMed ID: 23092789
[TBL] [Abstract][Full Text] [Related]
12. Absence of progression, not extent of tumour shrinkage, defines prognosis in soft-tissue sarcoma - An analysis of the EORTC 62012 study of the EORTC STBSG.
Grünwald V; Litière S; Young R; Messiou C; Lia M; Wardelmann E; van der Graaf W; Gronchi A; Judson I;
Eur J Cancer; 2016 Sep; 64():44-51. PubMed ID: 27323349
[TBL] [Abstract][Full Text] [Related]
13. Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG).
Sleijfer S; Ouali M; van Glabbeke M; Krarup-Hansen A; Rodenhuis S; Le Cesne A; Hogendoorn PC; Verweij J; Blay JY
Eur J Cancer; 2010 Jan; 46(1):72-83. PubMed ID: 19853437
[TBL] [Abstract][Full Text] [Related]
14. Current trials and new aspects in soft tissue sarcoma of adults.
Issels RD; Schlemmer M
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S4-8. PubMed ID: 12042982
[TBL] [Abstract][Full Text] [Related]
15. Predictive and prognostic factors associated with soft tissue sarcoma response to chemotherapy: a subgroup analysis of the European Organisation for Research and Treatment of Cancer 62012 study.
Young RJ; Litière S; Lia M; Hogendoorn PCW; Fisher C; Mechtersheimer G; Daugaard S; Sciot R; Collin F; Messiou C; Grünwald V; Gronchi A; van der Graaf W; Wardelmann E; Judson I
Acta Oncol; 2017 Jul; 56(7):1013-1020. PubMed ID: 28431480
[TBL] [Abstract][Full Text] [Related]
16. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
Judson I; Verweij J; Gelderblom H; Hartmann JT; Schöffski P; Blay JY; Kerst JM; Sufliarsky J; Whelan J; Hohenberger P; Krarup-Hansen A; Alcindor T; Marreaud S; Litière S; Hermans C; Fisher C; Hogendoorn PC; dei Tos AP; van der Graaf WT;
Lancet Oncol; 2014 Apr; 15(4):415-23. PubMed ID: 24618336
[TBL] [Abstract][Full Text] [Related]
17. Quality of surgery and neoadjuvant combined therapy in the ISG-GEIS trial on soft tissue sarcomas of limbs and trunk wall.
Gronchi A; Verderio P; De Paoli A; Ferraro A; Tendero O; Majò J; Martin J; Comandone A; Grignani G; Pizzamiglio S; Quagliuolo V; Picci P; Frustaci S; Dei Tos AP; Palassini E; Stacchiotti S; Ferrari S; Fiore M; Casali PG
Ann Oncol; 2013 Mar; 24(3):817-23. PubMed ID: 23110811
[TBL] [Abstract][Full Text] [Related]
18. A phase II study evaluating neo-/adjuvant EIA chemotherapy, surgical resection and radiotherapy in high-risk soft tissue sarcoma.
Schmitt T; Lehner B; Kasper B; Bischof M; Roeder F; Dietrich S; Dimitrakopoulou-Strauss A; Strauss LG; Mechtersheimer G; Wuchter P; Ho AD; Egerer G
BMC Cancer; 2011 Dec; 11():510. PubMed ID: 22152120
[TBL] [Abstract][Full Text] [Related]
19. The Impact of Perioperative Chemotherapy Timing in Conjunction With Postoperative External-Beam Radiation Therapy on Extremity Soft-Tissue Sarcomas Outcome.
Mahmoud O; Dosch A; Kwon D; Pitcher JD; Conway S; Benedetto P; Fernandez G; Trent J; Temple HT; Wolfson AH
Am J Clin Oncol; 2016 Oct; 39(5):528-34. PubMed ID: 24879472
[TBL] [Abstract][Full Text] [Related]
20. Effect of Neoadjuvant Chemotherapy Plus Regional Hyperthermia on Long-term Outcomes Among Patients With Localized High-Risk Soft Tissue Sarcoma: The EORTC 62961-ESHO 95 Randomized Clinical Trial.
Issels RD; Lindner LH; Verweij J; Wessalowski R; Reichardt P; Wust P; Ghadjar P; Hohenberger P; Angele M; Salat C; Vujaskovic Z; Daugaard S; Mella O; Mansmann U; Dürr HR; Knösel T; Abdel-Rahman S; Schmidt M; Hiddemann W; Jauch KW; Belka C; Gronchi A;
JAMA Oncol; 2018 Apr; 4(4):483-492. PubMed ID: 29450452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
